Cantor Fitzgerald Comments on TVTX FY2026 Earnings

Travere Therapeutics, Inc. (NASDAQ:TVTX) – Analysts at Cantor Fitzgerald issued their FY2026 EPS estimates for Travere Therapeutics in a report issued on Monday, June 9th. Cantor Fitzgerald analyst P. Agrawal forecasts that the company will post earnings per share of $1.86 for the year. Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Travere Therapeutics’ current full-year earnings is ($1.40) per share.

Travere Therapeutics (NASDAQ:TVTX) last released its quarterly earnings data on Thursday, May 1st. The company reported ($0.47) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.08. Travere Therapeutics had a negative net margin of 137.90% and a negative return on equity of 1,636.87%. The company had revenue of $81.73 million during the quarter, compared to analysts’ expectations of $77.44 million. During the same quarter in the previous year, the company earned ($1.76) earnings per share. The firm’s revenue for the quarter was up 83.3% on a year-over-year basis.

Several other equities analysts have also commented on TVTX. JPMorgan Chase & Co. upped their price objective on shares of Travere Therapeutics from $42.00 to $44.00 and gave the stock an “overweight” rating in a report on Wednesday, February 26th. Canaccord Genuity Group raised their price objective on shares of Travere Therapeutics from $45.00 to $47.00 and gave the company a “buy” rating in a report on Thursday, April 10th. Stifel Nicolaus increased their target price on shares of Travere Therapeutics from $22.00 to $23.00 and gave the company a “hold” rating in a research report on Friday, May 2nd. Citigroup lowered their price objective on shares of Travere Therapeutics from $35.00 to $32.00 and set a “buy” rating on the stock in a research report on Wednesday. Finally, Guggenheim reiterated a “buy” rating and issued a $47.00 price objective on shares of Travere Therapeutics in a research note on Monday, April 14th. Two equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $32.14.

Travere Therapeutics Stock Up 2.9%

Shares of NASDAQ TVTX opened at $14.94 on Wednesday. The company has a 50-day moving average of $16.87 and a 200 day moving average of $18.56. Travere Therapeutics has a 12-month low of $6.80 and a 12-month high of $25.29. The company has a current ratio of 1.71, a quick ratio of 1.68 and a debt-to-equity ratio of 24.96. The stock has a market cap of $1.33 billion, a PE ratio of -3.64 and a beta of 0.75.

Insider Activity at Travere Therapeutics

In other news, CEO Eric M. Dube sold 18,924 shares of Travere Therapeutics stock in a transaction that occurred on Monday, May 5th. The shares were sold at an average price of $21.05, for a total value of $398,350.20. Following the transaction, the chief executive officer now owns 419,173 shares of the company’s stock, valued at $8,823,591.65. The trade was a 4.32% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Peter Heerma sold 1,771 shares of the firm’s stock in a transaction on Monday, May 5th. The stock was sold at an average price of $21.05, for a total value of $37,279.55. Following the sale, the insider now directly owns 128,215 shares of the company’s stock, valued at approximately $2,698,925.75. This represents a 1.36% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 22,527 shares of company stock worth $473,814 in the last 90 days. Corporate insiders own 4.19% of the company’s stock.

Institutional Trading of Travere Therapeutics

A number of hedge funds have recently bought and sold shares of the company. Rhumbline Advisers lifted its stake in Travere Therapeutics by 2.7% during the first quarter. Rhumbline Advisers now owns 124,550 shares of the company’s stock valued at $2,232,000 after buying an additional 3,302 shares in the last quarter. Polar Asset Management Partners Inc. purchased a new stake in Travere Therapeutics during the first quarter valued at about $304,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Travere Therapeutics by 13.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 56,777 shares of the company’s stock valued at $1,029,000 after buying an additional 6,831 shares in the last quarter. Adage Capital Partners GP L.L.C. lifted its stake in Travere Therapeutics by 479.9% during the first quarter. Adage Capital Partners GP L.L.C. now owns 2,184,898 shares of the company’s stock valued at $39,153,000 after buying an additional 1,808,098 shares in the last quarter. Finally, PDT Partners LLC lifted its position in shares of Travere Therapeutics by 25.3% in the first quarter. PDT Partners LLC now owns 309,534 shares of the company’s stock worth $5,547,000 after purchasing an additional 62,425 shares in the last quarter.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.